Cagrilintide

Cagrilintide is supplied as a lyophilized (freeze-dried) white to off-white powder at a nominal quantity of 10 mg per vial. Purity is typically ≥98% as determined by HPLC analysis, with identity confirmed by mass spectrometry. A certificate of analysis (CoA) documenting purity, molecular weight, and lot-specific data is provided with each unit.

This material is characterized in standard in vitro laboratory systems (for example, receptor-expressing cell lines and biochemical assays). It is supplied for in vitro laboratory research use only and is not intended for human or animal use.

No. Cagrilintide supplied by this vendor is strictly for laboratory research use only. It has not been evaluated, approved, or formulated for human administration, therapeutic use, veterinary application, or food and drug product development. Researchers must comply with all applicable institutional and regulatory guidelines governing the use of research-grade peptides.

Cagrilintide acts as an agonist at amylin receptors, which are heterodimeric complexes comprising the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), forming AMY1, AMY2, and AMY3 receptor subtypes respectively. It also exhibits affinity for the calcitonin receptor alone. These molecular targets are the focus of in vitro pharmacological research using recombinant receptor expression systems and radioligand or BRET/FRET-based binding assays.